STOCK TITAN

NIH Selects ICF for $31 Million in Biomedical and Digital Modernization Work

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
ICF has been awarded two agreements by the National Institutes of Health (NIH) National Library of Medicine (NLM) with a combined value of $31 million. The first agreement is a multiple-award blanket purchase agreement (BPA) worth $4 million to collect and enhance access to biomedical and public health data. The second agreement is an 18-month, $27 million recompete contract for the operation, maintenance, and modernization of ClinicalTrials.gov. ICF will leverage its expertise and technology solutions to deliver accurate information for informed health decisions.
Positive
  • None.
Negative
  • None.

Services Will Accelerate Access to Public Health Data to Improve Health Outcomes

RESTON, Va., Nov. 1, 2023 /PRNewswire/ -- The National Institutes of Health (NIH) National Library of Medicine (NLM) recently awarded global consulting and technology services provider ICF (NASDAQ:ICFI) two agreements with a combined value of $31 million to provide biomedical and technical expertise, as well as data management and digital modernization services.

The first agreement is a new multiple-award blanket purchase agreement (BPA) to collect, curate, and enhance access to critical biomedical and public health data. ICF's efforts will improve data delivery to health researchers, professionals and the public so vital health decisions can quickly be made. The BPA has a term of three years, including a one-year base and two one-year options. ICF has also been awarded five new task orders under the BPA with a combined value of $4 million to provide health expertise, systems maintenance and long-range planning support.

The second agreement is an 18-month, $27 million recompete contract for the operation, maintenance and modernization of ClinicalTrials.gov, a project ICF has supported since 2009. The company will leverage its clinical research expertise and cutting-edge technology solutions to deliver scientifically accurate information to help patients, caregivers, healthcare professionals and researchers make more informed health decisions.

"As a longstanding partner to NIH and NLM, ICF has consistently provided complex technical and scientific expertise, advanced data analytics and enterprise-wide digital modernization and cloud services to support a wide range of critical agency programs," said Jennifer Welham, ICF senior vice president for health, people and human services. "We are eager to continue providing these skills and innovative solutions to further NLM's mission of enabling researchers, clinicians and the public to use the vast wealth of biomedical data for improved health."

For over 50 years, ICF has supported public health initiatives for nearly all major federal agencies, including numerous agencies and programs within the U.S. Department of Health and Human Services. The company's over 2,000 health professionals, including researchers, statisticians, epidemiologists, microbiologists, toxicologists, geneticists and more, work hand in hand with its over 2,000 technologists, data scientists and communicators to deliver mission critical programs that improve public health outcomes.

Read more about ICF's federal health and digital transformation services.

About ICF
ICF is a global consulting and technology services company with approximately 9,000 employees, but we are not your typical consultants. At ICF, business analysts and policy specialists work together with digital strategists, data scientists and creatives. We combine unmatched industry expertise with cutting-edge engagement capabilities to help organizations solve their most complex challenges. Since 1969, public and private sector clients have worked with ICF to navigate change and shape the future. Learn more at icf.com.

Caution Concerning Forward-looking Statements
Statements that are not historical facts and involve known and unknown risks and uncertainties are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such statements may concern our current expectations about our future results, plans, operations and prospects and involve certain risks, including those related to the government contracting industry generally; our particular business, including our dependence on contracts with U.S. federal government agencies; our ability to acquire and successfully integrate businesses; and the effects of the novel coronavirus disease (COVID-19), or any other future pandemic, and related national, state and local government actions and reactions, on the health of our staff and that of our clients, the continuity of our and our clients' operations, our results of operations and our outlook. These and other factors that could cause our actual results to differ from those indicated in forward-looking statements that are included in the "Risk Factors" section of our securities filings with the Securities and Exchange Commission. The forward-looking statements included herein are only made as of the date hereof, and we specifically disclaim any obligation to update these statements in the future.

Contact: Lauren Dyke, lauren.dyke@ICF.com, +1.571.373.5577

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nih-selects-icf-for-31-million-in-biomedical-and-digital-modernization-work-301974737.html

SOURCE ICF

FAQ

What agreements has ICF been awarded by the National Library of Medicine?

ICF has been awarded two agreements: a multiple-award blanket purchase agreement (BPA) and an 18-month recompete contract.

What is the value of these agreements?

The combined value of the agreements is $31 million. The BPA is worth $4 million, while the recompete contract is worth $27 million.

What services will ICF provide under the BPA?

ICF will collect, curate, and enhance access to critical biomedical and public health data under the BPA.

What is the duration of the BPA?

The BPA has a term of three years, including a one-year base and two one-year options.

What is the purpose of the second agreement?

The second agreement is for the operation, maintenance, and modernization of ClinicalTrials.gov.

How long is the second agreement?

The second agreement is an 18-month contract.

What is the goal of ICF's involvement in these agreements?

ICF aims to deliver accurate information for informed health decisions by leveraging its expertise and technology solutions.

ICF International, Inc.

NASDAQ:ICFI

ICFI Rankings

ICFI Latest News

ICFI Stock Data

2.28B
18.50M
1.39%
99.55%
2.47%
Consulting Services
Services-management Consulting Services
Link
United States of America
RESTON